REFRACTORY PRIMARY MEDIASTINAL (THYMIC) LARGE B-CELL LYMPHOMA
Clinical trials for REFRACTORY PRIMARY MEDIASTINAL (THYMIC) LARGE B-CELL LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new REFRACTORY PRIMARY MEDIASTINAL (THYMIC) LARGE B-CELL LYMPHOMA trials appear
Sign up with your email to follow new studies for REFRACTORY PRIMARY MEDIASTINAL (THYMIC) LARGE B-CELL LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug duo targets Hard-to-Treat lymphoma
Disease control Recruiting nowThis phase 2 trial tests whether combining two targeted drugs, loncastuximab tesirine and mosunetuzumab, can shrink tumors in people with diffuse large B-cell lymphoma that has relapsed or become resistant. The study will enroll 36 adults and measure how many patients respond and…
Matched conditions: REFRACTORY PRIMARY MEDIASTINAL (THYMIC) LARGE B-CELL LYMPHOMA
Phase: PHASE2 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
Engineered immune cells take on HIV-Linked cancers in first human trial
Disease control Recruiting nowThis study tests a CAR-T cell therapy (axicabtagene ciloleucel) in 20 HIV-positive adults whose aggressive B-cell lymphoma has come back or stopped responding to standard treatment. The therapy uses a patient's own immune cells, modified to recognize and attack cancer cells. The …
Matched conditions: REFRACTORY PRIMARY MEDIASTINAL (THYMIC) LARGE B-CELL LYMPHOMA
Phase: PHASE1 • Sponsor: AIDS Malignancy Consortium • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC